Xeris just posted its first profitable year in company history. Recorlev doubled revenue. The FDA rejected its main competitor. The Cushing's market is 5-10x larger than anyone models. Stock is down 42% from highs, RSI 25.

Sounds like a buy. It's not. Here's what actually matters — and it's not about XERS.

The Numbers

FY2025 was a genuine inflection. Not vibes. Not adjusted-non-GAAP-if-you-squint profitability. Real operating cash flow.

Revenue grew $89M while costs grew $30M. That's operating leverage, and it's real. The $0.6M GAAP net income is misleading — it's after $29M interest, $22M stock comp, and $11M amortization. The business generates $59M of EBITDA on $292M revenue. That's a 20% EBITDA margin in year one of profitability.

2026 guidance: $375-390M revenue (+30%+), EBITDA growing in absolute dollars. Management has a beat-and-raise pattern — guided $280-290M for FY2025 and delivered $292M.

Recorlev Is a Machine

The growth engine is Recorlev (levoketoconazole for Cushing's syndrome). Revenue doubled: $64M to $139M, +117% year-over-year. Volume-driven — 700 net new patients added in 2025, nearly doubling the patient base. Pricing was actually a drag (-7.2%). This is raw demand, not price hiking.

Three things make this interesting:

The competitor just died. Corcept's relacorilant — the most serious competitive threat — got a Complete Response Letter from FDA on December 30, 2025. Despite TWO trials meeting primary endpoints. Unusual rejection, but the result is clear: Recorlev's runway as the differentiated alternative to generic mifepristone just extended 12-24 months.

The market is expanding, not zero-sum. CORT posted $761M revenue in FY2025, growing 13% — simultaneously with Recorlev doubling. Both companies growing at the same time. The Cushing's/hypercortisolism market is demonstrably larger than the classic estimate of ≈25,000 US patients.

CATALYST blows the TAM open. CORT's CATALYST study found 1 in 4 patients with difficult-to-control Type 2 diabetes have hypercortisolism. That's not 25K patients. That's millions. CORT management is guiding "at least $2 billion annual revenue by end of decade" for the Cushing's market. XERS's $1B peak Recorlev estimate may be conservative.

And they just doubled the entire commercial team in January 2026 — sales, patient support, medical affairs, pharmacy services. A $45M SG&A bet that the TAM expansion is real.

XP-8121: The Empty Lane

Once-weekly subcutaneous levothyroxine for hypothyroidism. Phase 3 starting H2 2026. TAM: $1-3B peak.

The competitive landscape: nobody. Zero companies developing weekly SC levothyroxine. Searched 5,453 earnings transcripts. Nothing. The existing injectable products are IV formulations for acute hospital use, not outpatient maintenance. XeriSol formulation technology appears to be a genuine technical moat.

Phase 2 was clean — 4x dose conversion from oral, mostly mild TEAEs, no SAEs, published in a peer-reviewed journal. Phase 3 cost: ≈$25M incremental R&D, funded from operating cash flow. No equity raise needed.

If this works, XERS transforms from a $300M specialty pharma into something much larger. If it fails, they still have Recorlev growing toward $1B.

The Orphan Shield Nobody's Talking About

The One Big Beautiful Bill Act (signed July 4, 2025) expanded the IRA orphan drug exemption from Medicare price negotiation. Under the original IRA, only single-indication orphan drugs were exempt. OBBBA broadens this to ALL orphan drugs, effective from 2028.

This directly shields Recorlev from IRA pricing pressure through patent expiry in 2040.

How under-discussed is this? Of 5,453 earnings transcripts searched, only TWO explicitly mentioned the orphan drug pricing provision. 142 companies mentioned the Big Beautiful Bill — nearly all discussed tax benefits (R&D expensing, bonus depreciation). The orphan shield is hiding in plain sight.

This matters beyond XERS. Every orphan drug company with IRA pricing exposure just got structural protection that the market hasn't fully processed.

So Why Can't You Buy It?

59.8% idiosyncratic variance. Below the 75% threshold. XERS is 40% biotech sector beta. Its 1-year return (+37%) essentially tracks XBI (+42.6%). You're paying specialty pharma risk for index fund returns.

Both XERS and CORT are at RSI ≈25 simultaneously while XBI sits at 53. This isn't an XERS-specific oversold signal. It's sector rotation hitting small/mid biotech. The correlated selloff proves the point — if this were company-specific distress, CORT wouldn't track identically.

Seven analysts cover it. 86% Buy consensus. Mean target $11.14, implying 92% upside. If seven professional analysts see 92% upside and the stock keeps falling, either they're all wrong or the market knows something they don't. At $1B market cap, this is well outside the zone where retail has informational edge.

Insiders are selling. CEO and officers exercising options and distributing. No open-market purchases. If management believed their own $1B peak Recorlev forecast justified buying at $5.81 (42% below 52-week highs), they'd be accumulating. They're not.

$233M of debt at 11.4%. That's $29M per year in interest on $25M of operating income. Half of EBITDA goes to servicing debt. The $200M term loan has a pull-forward maturity to January 2028 if the $33.6M convertible notes aren't resolved. Manageable (convertibles are deep in-the-money at $3.06, holders will likely convert to equity), but the capital structure constrains everything.

What This Actually Tells You

XERS is the wrong vehicle for a right thesis. The interesting signals are:

Rare disease commercial inflection is real and can be dramatic. Recorlev went from $64M to $139M in one year on volume alone. This is what the orphan drug S-curve looks like when it works. If you're evaluating other rare disease names approaching commercial launch — and you should be — this is the benchmark.

OBBBA orphan shield is structural and under-priced. Every orphan drug company just got pricing protection the market hasn't fully processed. The ones already in our portfolio all have orphan designations. This removes a layer of bear-case risk that was real under the original IRA framework.

Cushing's TAM is a case study in market size surprise. CATALYST showing 1 in 4 resistant diabetics have hypercortisolism — when the classic estimate was 25K total patients — is the kind of TAM expansion that creates multi-year alpha. But the alpha was at $3-4 a year ago, not at $5.81 after a 37% run with seven analysts modeling the trajectory.

The right trade was XERS at $2-3 in 2023 when nobody believed Recorlev could drive profitability. That trade is done. What remains is a well-covered, sector-correlated specialty pharma where the inflection is consensus.

Evidence